The following is a summary of the BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript:

Financial Performance:

• BiomX reported a decrease in cash balance and short-term deposits from $34.3 million as of 2022 year-end to $15.9 million at the end of 2023, primarily due to operating activities.

• R&D expenses in 2023 slightly increased to $16.7 million from the $16.2 million of the previous year.

• G&A expenses diminished to $8.7 million in 2023 compared to $9.5 million in 2022.

• The firm presented a net loss of $26.2 million, better than the $28.3 million loss reported the previous year.

• BiomX raised $50 million via the acquisition of Adaptive Phage Therapeutics (APT), expected to finance operations for at least the coming year.

Business Progress:

• The company announced promising results for Part 2 of their Phase 1b/2a study of BX004.

• The acquisition of APT added another Phase 2 product candidate, BX211, for treating diabetic foot osteomyelitis (DFO).

• The procurement of Adaptive Phage Therapeutics raised about $50 million from various investors.

• BiomX emerged as a front-running phage company with an advanced pipeline of phage-based therapeutics after acquiring APT.

• Successful readout for Phase 2 is projected for BX004 and BX211 in 2025.

• A randomized double-blind placebo-controlled multicenter Phase 2 study for BX211 is in progress, with results expected in Q1, 2025.

• BiomX also plans to discuss the clinical development plan for BX004 with the FDA in Q2, 2024 and anticipates releasing top-line results from this study in Q3, 2025.

More details: BiomX IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.